Cancer genes hijack enhancers

June 23, 2014

Unlike most other forms of cancer, medulloblastomas exhibits very few mutations in growth-promoting genes. In collaboration with an international team of colleagues, scientists from the German Cancer Research Center have now made an important discovery about a particularly malignant subgroup of medulloblastomas: often the cancer-causing genes are transcribed at higher or lower levels than normal. This change is due to regulatory mechanisms that were previously unknown. For example, one cancer-gene hijacks a so-called 'enhancer.'

Medulloblastoma is the most common childhood brain tumor. It is classified in four distinct subgroups that vary strongly in terns of the aggressiveness of the disease. Group 3 and Group 4 tumors, which are very challenging, are particularly common. "For these two tumor groups, hardly any characteristic genomic changes that drive tumor growth and would make potential targets for drug development have been identified," says Prof. Dr. Peter Lichter from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), who is coordinator of the PedBrain Tumor network. The PedBrain network is part of the International Cancer Genome Consortium (ICGC), whose researchers are systematically analyzing all genomic alterations in pediatric to discover new targets for the development of gentler modes of treatment.

Dr. Paul Northcott and coworkers from the first team took a closer look at 137 cases of the more aggressive Group 3 and Group 4 . They discovered a phenomenon that had never been observed before in brain cancer. In many of the tumor genomes, large regions of DNA had been deleted or duplicated or had changed their orientation. Despite their different nature, these structural changes had identical consequences in all tumors under investigation: One of two oncogenes called GFI1 and GFI1B, which are not active in healthy brain tissue, is transcribed in these tumors and thus contributes to the development of cancer.

The PedBrain researchers also discovered what causes this strange phenomenon. Various structural changes had moved the oncogene from a usually inactive environment to a position close to DNA sequences called "enhancers", which are involved in the activation of genes. In mice, the researchers subsequently proved that activated GFI1B leads to the development of brain cancer, providing evidence that the "hijacked" gene enhancers promote the onset of cancer.

"It is quite possible that hijacked enhancers also play a role as activating mechanisms in many other types of cancer," says Prof. Dr. Stefan Pfister, a molecular geneticist at the DKFZ, who also works as a pediatrician at Heidelberg University Hospital. "However, one can only discover them through a very careful analysis of the genome, and therefore they are easily missed."

The researchers are particularly pleased that their work may directly contribute to the development of better treatments for children with brain cancer. Substances that block the effects of the GFI1 and GFI1B oncogenes are already being tested in clinical trials and might now also be used to slow down the growth of aggressive Group 3 and Group 4 medulloblastomas.

The second team focused their investigations on the so-called "epigenetic" regulation of gene activity by chemical labels in DNA. The researchers compared patterns of DNA methylation across the whole genome from 42 medulloblastomas with the patterns found in healthy control tissue.

The number of methylation groups found in the promoter region, i.e., the region of DNA that stimulates the transcription of a gene, has been considered a crucial factor in gene activity. For the first time, Volker Hovestadt and his colleagues have discovered that altered methyl groups within genes also are also relevant to their activation. Numerous genes in tumor cells exhibited low levels of methylation compared to healthy counterparts. At the same time, they were transcribed significantly more frequently than in healthy cells. This is clear evidence that a lack of methyl groups has functional effects.

"The regulation of by methyl labels within a particular gene has never been observed, at least not to such a marked extent," Lichter says. "In some of the tumors we found nearly 1000 genes that were methylated at lower levels than their counterparts in healthy cells."

PedBrain network coordinator Lichter summarized the relevance of the two Nature publications: "The results show the major relevance of the epigenetic regulation of genes, including known oncogenes, in medulloblastoma. In addition, we have identified GFl1 and GFl1B as an Achilles' heel of the most dangerous types of medulloblastoma. For the first time, this reveals a molecular weak spot in these tumors that can be targeted in drug development."

Explore further: Overlooked DNA shuffling drives deadly paediatric brain tumour

More information: Volker Hovestadt, David T. W. Jones, …, Bernhard Radlwimmer, Stefan M. Pfister und Peter Lichter im Auftrag des ICGC PedBrain Tumor Project: Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014, DOI: 10.1038/nature13268

Paul A Northcott, Catherine Lee, Thomas Zichner, …, Peter Lichter, Jan O Korbel, Robert J Wechsler-Reya und Stefan M Pfister im Auftrag des ICGC PedBrain Tumor Project: Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014, DOI: 10.1038/nature13379

Related Stories

Overlooked DNA shuffling drives deadly paediatric brain tumour

June 23, 2014
One of the deadliest forms of paediatric brain tumour, Group 3 medulloblastoma, is linked to a variety of large-scale DNA rearrangements which all have the same overall effect on specific genes located on different chromosomes. ...

Genome analysis of brain tumors showing the way to new treatment strategies

July 26, 2012
Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood ...

Suspicions confirmed: Brain tumors in children have a common cause

July 9, 2013
An overactive signaling pathway is a common cause in cases of pilocytic astrocytoma, the most frequent type of brain cancer in children. This was discovered by a network of scientists coordinated by the German Cancer Research ...

Enzyme that silences DNA activity may be crucially involved in health and cancer

April 23, 2014
Cancers can develop when the complex molecular networks that control the activity of DNA are disrupted. Researchers from the A*STAR Institute of Molecular and Cell Biology in Singapore, led by Dmitry Bulavin, have studied ...

Linking risk factors and disease origins in breast cancer

November 20, 2013
Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe ...

How breast cancer 'expresses itself'

May 29, 2014
About one in eight women in the United States will contract breast cancer in her lifetime. Now new research from Tel Aviv University-affiliated researchers, in collaboration with Johns Hopkins University, has provided another ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.